ConforMIS News

  • Tuesday, 2/26/08

    ConforMIS to Present at Canaccord Adams Orthopedics Conference

    Burlington, Mass. – February 26, 2008 – ConforMIS, Inc., a privately held company that develops and commercializes minimally invasive medical devices for the treatment of osteoarthritis and joint damage, announced today that Dr. Philipp Lang, chairman and CEO of ConforMIS, will present at the Canaccord Adams Small-Cap Orthopedics Conference at the Mission Bay Conference Center in San Francisco on March 4, 2008.

    Dr. Lang will deliver the presentation at approximately 8:10 a.m. PST as part of a block of private companies speaking at the conference. During the presentation, Dr. Lang will provide background information on ConforMIS as well as updates on the company’s ‘image-to-implant’ technology platforms known as the iFit™ Technology and the iJig™ Instrumentation. He will also discuss the opportunity for personalized medicine in orthopedics and the knee replacement market.

    For additional information on ConforMIS, please visit http://www.conformis.com/.

    About ConforMIS, Inc. 
    ConforMIS, Inc. is a privately held company that develops and commercializes medical devices for the treatment of osteoarthritis and joint damages. The Company’s novel and scaleable ‘image-to-implant’ process is comprised of two related technology platforms. iFit™ Technology enables the creation of conforming, patient-specific implants that are precisely sized and shaped to match the 3D topography of the patient’s anatomy. iJig™ Instrumentation enables the creation of disposable, easy-to-use instrumentation that simplifies the surgical process and improves reproducibility.

    Both platforms are supported by proprietary, intellectual property consisting of more than 120 patents and pending patent applications that span imaging software, image processing, implant design, surgical techniques and instrumentation.

    To date, ConforMIS has developed a comprehensive line of minimally traumatic, bone and cartilage-preserving knee implants and instrumentation designed to address all stages of osteoarthritis. Each of these devices has been cleared by the US Food and Drug Administration for marketing in the U.S.

    About Canaccord Adams
    Canaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, our 225 professionals seek out emerging opportunities in our key sectors – Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, our experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.